Next Article in Journal
Virus-Like Particles of Chimeric Recombinant Porcine Circovirus Type 2 as Antigen Vehicle Carrying Foreign Epitopes
Previous Article in Journal
Genotypic Analysis of Kaposi’s Sarcoma-Associated Herpesvirus from Patients with Kaposi’s Sarcoma in Xinjiang, China
Previous Article in Special Issue
Integration Site and Clonal Expansion in Human Chronic Retroviral Infection and Gene Therapy
Review

Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy

1
Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
2
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
Viruses 2014, 6(12), 4811-4838; https://doi.org/10.3390/v6124811
Received: 26 September 2014 / Revised: 7 November 2014 / Accepted: 20 November 2014 / Published: 5 December 2014
(This article belongs to the Special Issue Retroviral Vectors)
Gene therapy using integrating retroviral vectors has proven its effectiveness in several clinical trials for the treatment of inherited diseases and cancer. However, vector-mediated adverse events related to insertional mutagenesis were also observed, emphasizing the need for safer therapeutic vectors. Paradoxically, alpharetroviruses, originally discovered as cancer-causing agents, have a more random and potentially safer integration pattern compared to gammaretro- and lentiviruses. In this review, we provide a short overview of the history of alpharetroviruses and explain how they can be converted into state-of-the-art gene delivery tools with improved safety features. We discuss development of alpharetroviral vectors in compliance with regulatory requirements for clinical translation, and provide an outlook on possible future gene therapy applications. Taken together, this review is a broad overview of alpharetroviral vectors spanning the bridge from their parental virus discovery to their potential applicability in clinical settings. View Full-Text
Keywords: retrovirology; alpharetroviral vector; gene therapy; clinical translation; regulatory requirements; vector safety retrovirology; alpharetroviral vector; gene therapy; clinical translation; regulatory requirements; vector safety
Show Figures

Figure 1

MDPI and ACS Style

Suerth, J.D.; Labenski, V.; Schambach, A. Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy. Viruses 2014, 6, 4811-4838. https://doi.org/10.3390/v6124811

AMA Style

Suerth JD, Labenski V, Schambach A. Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy. Viruses. 2014; 6(12):4811-4838. https://doi.org/10.3390/v6124811

Chicago/Turabian Style

Suerth, Julia D., Verena Labenski, and Axel Schambach. 2014. "Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy" Viruses 6, no. 12: 4811-4838. https://doi.org/10.3390/v6124811

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop